Choroidal Neovascularization — Pipeline Review, H2
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Choroidal Neovascularization Pipeline Review, H2 2017, provides an overview of the Choroidal Neovascularization Ophthalmology pipeline landscape.
Choroidal neovascularization CNV involves the growth of new blood vessels that originate from the choroid Symptoms include painless loss of vision, metamorphopsia, and color disturbances. Treatment includes antVEGF agents, laser photocoagulation and photodynamic therapy.
Download FREE Sample of this Report @ https://www.24marketreports.com/report-sample/choroidal-neovascularization---pipeline-review-h2-2017-market-108
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Choroidal Neovascularization Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Choroidal Neovascularization Ophthalmology, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Choroidal Neovascularization Ophthalmology pipeline guide also reviews of key players involved in therapeutic development for Choroidal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Choroidal Neovascularization Ophthalmology pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization Ophthalmology.
The pipeline guide reviews pipeline therapeutics for Choroidal Neovascularization Ophthalmology by companies and universities/research institutes based on information derived from company and industryspecific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Choroidal Neovascularization Ophthalmology therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Choroidal Neovascularization Ophthalmology therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Choroidal Neovascularization Ophthalmology
Get the Complete Report & TOC @ https://www.24marketreports.com/life-sciences/choroidal-neovascularization---pipeline-review-h2-2017-market-108
Table of content
Introduction
Global Markets Direct Report Coverage
Choroidal Neovascularization Overview
Choroidal Neovascularization Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Choroidal Neovascularization Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Choroidal Neovascularization Companies Involved in Therapeutics Development
F. HoffmannLa Roche Ltd
Formycon AG
Graybug Vision Inc
Isarna Therapeutics GmbH
Lupin Ltd
Mabion SA
NovelMed Therapeutics Inc
Noxxon Pharma AG
Promedior Inc
Choroidal Neovascularization Drug Profiles
ACX107 Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar Drug Profile
Product Description
Mechanism Of Action
R&D Progress
If You Have Any Question Related To This Report Contact Us @ https://www.24marketreports.com/enquire-now/choroidal-neovascularization---pipeline-review-h2-2017-market-108
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: [email protected]
Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports